circPTPRA was shown to suppress the progression of bladder cancer, through its interaction with IGF2BP1, an N6-methyladenosine (m6A) reader, and blocking the IGF2BP1-mediated recognition of m6A-modified RNAs [47]. Here, IGF2BP1 is linked to urinary bladder carcinoma.